
Opinion|Videos|June 3, 2024
Alzheimer’s Disease Pipeline
Key opinion leaders discuss the Alzheimer's disease pipeline and the numerous disease-modifying therapies under investigation.
Advertisement
Episodes in this series

Video content above is prompted by the following question:
- Please provide an overview of robust Alzheimer’s pipeline and many disease modifying therapies under investigation.
- Discuss novel and emerging treatments that are most advanced in clinical studies or have promising data:
- Valiltramiprosate (ALZ-801,inhibits amyloid oligomer formation, oral)
- ALN-APP (RNAi therapeutic)
- Blarcamesine (sigma-1 and muscarinic receptors ligand)
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves At-Home Starting Dose for Lecanemab, Marking First Subcutaneous Initiation Option for Alzheimer Disease Treatment
2
Phase 2 APPLAUDS Trial to Test Mivelsiran in Down Syndrome-Associated Alzheimer Disease
3
Mitophagy Activator Urolithin A Enters Phase 2 Alzheimer Trial of APOE4 Carriers
4
Inside the World's First Neural Stem Cell Trial for Huntington Disease
5



















